Literature DB >> 11882474

Circulating testosterone and prostate-specific antigen in nipple aspirate fluid and tissue are associated with breast cancer.

Edward R Sauter1, David S Tichansky, Inna Chervoneva, Eleftherios P Diamandis.   

Abstract

Preliminary evidence has associated testosterone and prostate-specific antigen (PSA) with breast cancer. Our objective was to determine whether a) testosterone levels in nipple aspirate fluid (NAF), serum, or breast tissue are associated with breast cancer; b) testosterone levels in serum are associated with levels in NAF; c) PSA in NAF, serum, or breast tissue is associated with breast cancer; and d) serum PSA is associated with NAF PSA levels. We obtained 342 NAF specimens from 171 women by means of a modified breast pump. Additionally, we collected 201 blood samples from 99 women and 51 tissue samples from 41 subjects who underwent surgical resection for suspected disease. Women currently using birth control pills or hormone replacement therapy were excluded from the study. Controlling for age and menopausal status, serum testosterone was significantly increased in women with breast cancer (p = 0.002). NAF and serum testosterone levels were not associated. Neither NAF nor tissue testosterone was associated with breast cancer. Controlling for menopausal status and age, NAF PSA was significantly decreased in women with breast cancer (p < 0.001). We did not find serum PSA to be associated with breast cancer, although we found an indication that, in postmenopausal women, its levels were lower in women with cancer. Serum PSA was associated with NAF PSA in postmenopausal women (p < 0.001). PSA levels in cancerous tissue were significantly lower than in benign breast specimens from subjects without cancer (p = 0.011), whereas levels of PSA in histologically benign specimens from subjects with cancer were intermediate. Our results suggest that serum testosterone is increased and NAF PSA is decreased in women with breast cancer, with PSA expression being higher in normal than in cancerous breast tissues. NAF and serum PSA levels in postmenopausal women are correlated, suggesting that as laboratory assessment of PSA becomes more sensitive, serum PSA may become useful in identifying women with breast cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11882474      PMCID: PMC1240763          DOI: 10.1289/ehp.02110241

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  37 in total

1.  Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers.

Authors:  R A Ferguson; H Yu; M Kalyvas; S Zammit; E P Diamandis
Journal:  Clin Chem       Date:  1996-05       Impact factor: 8.327

2.  Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women.

Authors:  S E Hankinson; W C Willett; J E Manson; G A Colditz; D J Hunter; D Spiegelman; R L Barbieri; F E Speizer
Journal:  J Natl Cancer Inst       Date:  1998-09-02       Impact factor: 13.506

3.  Decreased apoptosis in non-involved tissue from cancer-containing breasts.

Authors:  H I Hassan; R A Walker
Journal:  J Pathol       Date:  1998-03       Impact factor: 7.996

4.  Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.

Authors:  M F Darson; A Pacelli; P Roche; H G Rittenhouse; R L Wolfert; C Y Young; G G Klee; D J Tindall; D G Bostwick
Journal:  Urology       Date:  1997-06       Impact factor: 2.649

5.  Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue.

Authors:  H Yu; E P Diamandis; M Levesque; M Giai; R Roagna; R Ponzone; P Sismondi; M Monne; C M Croce
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

6.  Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women.

Authors:  A Zeleniuch-Jacquotte; P F Bruning; J M Bonfrer; K L Koenig; R E Shore; M Y Kim; B S Pasternack; P Toniolo
Journal:  Am J Epidemiol       Date:  1997-06-01       Impact factor: 4.897

7.  Nonprostatic sources of prostate-specific antigen.

Authors:  E P Diamandis; H Yu
Journal:  Urol Clin North Am       Date:  1997-05       Impact factor: 2.241

8.  Serum sex hormone levels are related to breast cancer risk in postmenopausal women.

Authors:  J F Dorgan; C Longcope; H E Stephenson; R T Falk; R Miller; C Franz; L Kahle; W S Campbell; J A Tangrea; A Schatzkin
Journal:  Environ Health Perspect       Date:  1997-04       Impact factor: 9.031

9.  A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey.

Authors:  H V Thomas; T J Key; D S Allen; J W Moore; M Dowsett; I S Fentiman; D Y Wang
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer.

Authors:  N Zarghami; L Grass; E P Diamandis
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  5 in total

1.  Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element.

Authors:  Marilena Lanzino; Diego Sisci; Catia Morelli; Cecilia Garofalo; Stefania Catalano; Ivan Casaburi; Claudia Capparelli; Cinzia Giordano; Francesca Giordano; Marcello Maggiolini; Sebastiano Andò
Journal:  Nucleic Acids Res       Date:  2010-04-26       Impact factor: 16.971

2.  Protein Biomarkers for Breast Cancer Risk Are Specifically Correlated with Local Steroid Hormones in Nipple Aspirate Fluid.

Authors:  Ali Shidfar; Tolulope Fatokun; David Ivancic; Robert T Chatterton; Seema A Khan; Jun Wang
Journal:  Horm Cancer       Date:  2016-04-19       Impact factor: 3.869

3.  Androgens downregulate miR-21 expression in breast cancer cells underlining the protective role of androgen receptor.

Authors:  Ivan Casaburi; Maria Grazia Cesario; Ada Donà; Pietro Rizza; Saveria Aquila; Paola Avena; Marilena Lanzino; Michele Pellegrino; Adele Vivacqua; Paola Tucci; Catia Morelli; Sebastiano Andò; Diego Sisci
Journal:  Oncotarget       Date:  2016-03-15

Review 4.  Nipple Aspirate Fluid at a Glance.

Authors:  Susana I S Patuleia; Karijn P M Suijkerbuijk; Elsken van der Wall; Paul J van Diest; Cathy B Moelans
Journal:  Cancers (Basel)       Date:  2021-12-29       Impact factor: 6.639

Review 5.  Evaluation of nipple aspirate fluid as a diagnostic tool for early detection of breast cancer.

Authors:  Sadr-Ul Shaheed; Catherine Tait; Kyriacos Kyriacou; Richard Linforth; Mohamed Salhab; Chris Sutton
Journal:  Clin Proteomics       Date:  2018-01-11       Impact factor: 3.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.